In vivo Targeting of Dead Tumor Cells in a Murine Tumor Model Using a Monoclonal Antibody Specific for the La Autoantigen

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-0964PMID 17875784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• Positron emission tomography as an imaging biomarker.

  2006cited by this paper
• Update: Recombinant Antibodies: From the Laboratory to the Clinic

  2006cited by this paper
• Drug Insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms

  2006cited by this paper
• Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

  2005cited by this paper
• The role of apoptosis in cancer development and treatment response

  2005cited by this paper
• Apoptosis-detecting radioligands: current state of the art and future perspectives

  2004cited by this paper
• Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper.

  2004cited by this paper
• Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin.

  2004cited by this paper
• Chemotherapy‐Induced Apoptosis and Bcl‐2 Levels Correlate with Breast Cancer Response to Chemotherapy

  2003cited by this paper
• Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.

  2003cited by this paper
• Synthesis, characterization, and X-ray crystal structure of In(DOTA-AA) (AA = p-aminoanilide): a model for 111In-labeled DOTA-biomolecule conjugates.

  2003cited by this paper
• Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist.

  2003cited by this paper
• Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography.

  2003cited by this paper
• Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals.

  2003cited by this paper
• In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope

  2003cited by this paper
• Near-infrared fluorescent imaging of tumor apoptosis.

  2003cited by this paper
• Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.

  2003cited by this paper
• Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-annexin V.

  2003cited by this paper
• Apoptosis A Link between Cancer Genetics and Chemotherapy

  2002cited by this paper
• Bystander effect produced by radiolabeled tumor cells in vivo

  2002cited by this paper
• Pharmacokinetic Characteristics and Biodistribution of Radioiodinated Chimeric TNT-1, -2, and -3 Monoclonal Antibodies After Chemical Modification with Biotin

  2002cited by this paper
• Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.

  2002cited by this paper
• Detection of in situ activation of transglutaminase during apoptosis: correlation with the cell cycle phase by multiparameter flow and laser scanning cytometry.

  2002cited by this paper
• Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent

  2001cited by this paper
• Stabilization of 90Y-Labeled DOTA-Biomolecule Conjugates Using Gentisic Acid and Ascorbic Acid

  2001cited by this paper
• Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.

  2001cited by this paper
• Stabilization of (90)y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid.

  2001cited by this paper
• Synthesis and characterization of two (111)In-labeled DTPA-peptide conjugates.

  2001cited by this paper
• Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma

  2000cited by this paper
• Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.

  2000cited by this paper
• Mass spectrometric immunoassay for parathyroid hormone-related protein.

  2000cited by this paper
• Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors.

  2000cited by this paper
• Enhancement of tumor radioresponse in vivo by gemcitabine.

  1999cited by this paper
• Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates.

  1999cited by this paper
• In vivo detection and imaging of phosphatidylserine expression during programmed cell death.

  1998cited by this paper
• A New Chemically Modified Chimeric TNT-3 Monoclonal Antibody Directed Against DNA for the Radioimmunotherapy of Solid Tumors

  1998cited by this paper
• Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.

  1996cited by this paper
• Immunologic and Biochemical Analysis of TNT-1 and TNT-2 Monoclonal Antibody Binding to Histones

  1993cited by this paper
• Cancer imaging with CEA antibodies: historical and current perspectives.

  1992cited by this paper
• Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates.

  1992cited by this paper
• Persistent uptake of indium-111-antimyosin monoclonal antibody in patients with myocardial infarction.

  1990cited by this paper
• Imaging of soft-tissue sarcomas with indium-111-labeled monoclonal antimyosin Fab fragments.

  1990cited by this paper
• Indium-111-antimyosin antibody imaging for detecting different stages of myocardial infarction: comparison with technetium-99m-pyrophosphate imaging.

  1990cited by this paper
• Indium-111-antimyosin images compared with triphenyl tetrazolium chloride staining in a patient six days after myocardial infarction.

  1990cited by this paper
• Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody.

  1989cited by this paper
• A novel method for the detection of necrotic lesions in human cancers.

  1988cited by this paper
• Endothelial injury caused by antineoplastic agents.

  1986cited by this paper
• Cell death: the significance of apoptosis.

  1980cited by this paper
• Specificity of Localization of Myosin‐specific Antibody Fragments in Experimental Myocardial Infarction: Histologic, Histochemical, Autoradiographic and Scintigraphic Studies

  1979cited by this paper
• Localization of Radiolabeled Cardiac Myosin‐Specific Antibody in Myocardial Infarcts: Comparison with Technetium‐99m Stannous Pyrophosphate

  1977cited by this paper

• Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®

  2025cites this paper
• Imaging of cell death in malignancy: Targeting pathways or phenotypes?

  2023cites this paper
• Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®.

  2022cites this paper
• The RNA‐binding protein La/SSB associates with radiation‐induced DNA double‐strand breaks in lung cancer cell lines

  2021cites this paper
• Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody.

  2020cites this paper
• Imaging cell death: focus on early evaluation of tumor response to therapy.

  2020cites this paper
• Positron Emission Tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian cancer xenograft models

  2020cites this paper
• A Novel Sulfonyl-Based Small Molecule Exhibiting Anti-cancer Properties

  2020cites this paper
• Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

  2020cites this paper
• Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®

  2020cites this paper
• Updated developments on molecular imaging and therapeutic strategies directed against necrosis

  2019cites this paper
• APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo

  2018cites this paper
• Avenues to molecular imaging of dying cells: Focus on cancer

  2018cites this paper
• Increased liver tumor formation in neutral sphingomyelinase-2-deficient mice

  2018cites this paper
• Selectivity Conversion of Protease Inhibitory Antibodies

  2018cites this paper
• Proteomic characterization of EL4 lymphoma‐derived tumors upon chemotherapy treatment reveals potential roles for lysosomes and caspase‐6 during tumor cell death in vivo

  2017cites this paper
• Targeting Phosphatidylserine with a 64Cu-Labeled Peptide for Molecular Imaging of Apoptosis.

  2016cites this paper
• Radiopharmacological evaluation of (18)F-labeled phosphatidylserine-binding peptides for molecular imaging of apoptosis.

  2015cites this paper
• The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®

  2014cites this paper
• Visualization of Proteins and Cells Using Dithiol‐reactive Metal Complexes

  2014cites this paper
• Monte Carlo simulations of dose distributions with necrotic tumor targeted radioimmunotherapy.

  2014cites this paper
• Targeted &agr;-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation

  2014cites this paper
• Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB4 Monoclonal Antibody Relates to Apoptotic Cell Clearance

  2014influential citation
• Monoclonal Antibody Relates to Apoptotic Cell Clearance Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB 4

  2014influential citation
• Optical imaging of treatment-related tumor cell death using a heat shock protein-90 alkylator.

  2013cites this paper
• A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.

  2012cites this paper
• Biomarkers and molecular probes for cell death imaging and targeted therapeutics.

  2012cites this paper
• Prediction of Novel Pathway Elements and Interactions Using Bayesian Networks

  2011cites this paper
• Bayesian Network Approaches for Refining and Expanding Cellular and Immunological Pathways.

  2011cites this paper
• Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes

  2010cites this paper
• Chemotherapy Synergizes with Radioimmunotherapy Targeting La Autoantigen in Tumors

  2009cites this paper
• APOMAB®, a La-Specific Monoclonal Antibody, Detects the Apoptotic Tumor Response to Life-Prolonging and DNA-Damaging Chemotherapy

  2009influential citation
• Immunotargeting of Functional Nanoparticles for MRI detection of Apoptotic Tumor Cells

  2009cites this paper
• A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution.

  2009cites this paper